MiMedx Group Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de MiMedx Group disminuyan a un ritmo anual de 2%, mientras que sus ingresos anuales crecerán a un ritmo de 3.8% por año. Se espera que el BPA disminuya en un 5.3% al año.

Información clave

-2.0%

Tasa de crecimiento de los beneficios

-5.28%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	22.7%
Tasa de crecimiento de los ingresos	3.8%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	26 Feb 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio

Apr 17

MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly

Mar 27

Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings

Mar 05

Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors

Feb 22

We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease

Dec 23

We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease

Nov 21

There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise

Nov 06

HELIOGEN's Launch And Scientific Breakthroughs Promise Growth Amid Reimbursement And Legal Challenges

Sep 24 The launch of HELIOGEN and strategic expansions in the surgical market underscore innovation and efforts to boost revenue through new market penetration and customer loyalty.

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

May 21

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

May 14

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Mar 27

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Jan 05

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 18

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

Aug 08

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:MDXG - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2028	434	58	80	82	2
12/31/2027	393	37	66	64	6
12/31/2026	347	13	39	41	6
12/31/2025	419	49	73	74	N/A
9/30/2025	393	41	67	68	N/A
6/30/2025	364	32	57	58	N/A
3/31/2025	352	40	64	66	N/A
12/31/2024	349	42	65	66	N/A
9/30/2024	343	79	56	58	N/A
6/30/2024	340	79	48	51	N/A
3/31/2024	335	68	34	37	N/A
12/31/2023	321	56	25	27	N/A
9/30/2023	309	19	8	11	N/A
6/30/2023	295	2	-4	-1	N/A
3/31/2023	281	-18	-15	-12	N/A
12/31/2022	268	-27	-19	-18	N/A
9/30/2022	261	-34	-17	-16	N/A
6/30/2022	256	-28	-12	-10	N/A
3/31/2022	258	-19	-7	-6	N/A
12/31/2021	242	-18	-5	-2	N/A
9/30/2021	260	-35	-14	-9	N/A
6/30/2021	261	-83	-25	-20	N/A
3/31/2021	246	-88	-30	-25	N/A
12/31/2020	248	-83	-35	-30	N/A
9/30/2020	256	-73	-46	-43	N/A
6/30/2020	281	-8	-44	-42	N/A
3/31/2020	294	-17	-39	-36	N/A
12/31/2019	299	-26	-42	-39	N/A
9/30/2019	315	-54	N/A	-15	N/A
6/30/2019	314	-67	N/A	-8	N/A
3/31/2019	342	-48	N/A	10	N/A
12/31/2018	359	-30	N/A	36	N/A
9/30/2018	354	41	N/A	55	N/A
6/30/2018	352	59	N/A	70	N/A
3/31/2018	333	65	N/A	62	N/A
12/31/2017	321	65	N/A	63	N/A
9/30/2017	303	35	N/A	59	N/A
6/30/2017	283	21	N/A	44	N/A
3/31/2017	264	15	N/A	37	N/A
12/31/2016	222	0	N/A	24	N/A
9/30/2016	227	20	N/A	14	N/A
6/30/2016	212	23	N/A	18	N/A
3/31/2016	200	27	N/A	14	N/A
12/31/2015	187	29	N/A	19	N/A
9/30/2015	175	20	N/A	23	N/A
6/30/2015	160	17	N/A	24	N/A
3/31/2015	139	11	N/A	23	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de MDXG disminuyan en los próximos 3 años (-2% al año).

Beneficios vs. Mercado: Se prevé que los beneficios de MDXG disminuyan en los próximos 3 años (-2% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de MDXG disminuyan en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (3.8% al año) de MDXG crezcan más despacio que el mercado de US (10.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 3.8% al año) de MDXG crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de MDXG se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/03/06 13:16
Precio de las acciones al final del día	2026/03/06 00:00
Beneficios	2025/12/31
Ingresos anuales	2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

MiMedx Group, Inc. está cubierta por 10 analistas. 6 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
William Plovanic	Canaccord Genuity
Ross Osborn	Cantor Fitzgerald & Co.
David Turkaly	Citizens JMP Securities, LLC

MiMedx Group Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates fall by 35%

Price target decreased by 12% to US$10.40

Price target decreased by 8.3% to US$11.00

Consensus EPS estimates increase by 41%

MiMedx Group, Inc. Raises Earnings Guidance for the Year 2025

MiMedx Group, Inc. Provides Revenue Guidance for the Full Year 2025

Recent updates

MiMedx Group, Inc. Expands Surgical Product Portfolio with the Launch of AMNIOFIX Thyroid Shields

Consensus EPS estimates fall by 35%

New major risk - Revenue and earnings growth

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

MiMedx Group, Inc. (NasdaqCM:MDXG) announces an Equity Buyback for $100 million worth of its shares.

MiMedx Group, Inc. to Report Q4, 2025 Results on Feb 25, 2026

Insufficient new directors

Price target decreased by 12% to US$10.40

Price target decreased by 8.3% to US$11.00

Investors Interested In MiMedx Group, Inc.'s (NASDAQ:MDXG) Earnings

Mimedx Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts in Vitro

Mimedx Provides Update on Epieffect®? Randomized Controlled Trial

Chief Commercial Officer recently sold US$432k worth of stock

MiMedx Group's (NASDAQ:MDXG) Soft Earnings Don't Show The Whole Picture

Consensus EPS estimates increase by 41%

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. Raises Earnings Guidance for the Year 2025

MiMedx Group, Inc. to Report Q3, 2025 Results on Oct 29, 2025

MiMedx Group, Inc. Announces Launch of EPIXPRESS

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. Provides Revenue Guidance for the Full Year 2025

MiMedx Group, Inc. to Report Q2, 2025 Results on Jul 30, 2025

MiMedx Group (NASDAQ:MDXG) Could Easily Take On More Debt

MiMedx Group, Inc.(NasdaqCM:MDXG) dropped from Russell 3000E Value Index

MiMedx Group, Inc. Elects M. Kathleen Behrens as Director

CEO & Director recently bought US$1.3m worth of stock

Investor sentiment improves as stock rises 17%

Consensus EPS estimates fall by 11%

Price target decreased by 9.0% to US$12.20

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

MiMedx Group, Inc., Annual General Meeting, Jun 18, 2025

Some Shareholders Feeling Restless Over MiMedx Group, Inc.'s (NASDAQ:MDXG) P/E Ratio

MiMedx Group, Inc. to Report Q1, 2025 Results on Apr 30, 2025

MiMedx Group (NASDAQ:MDXG) Seems To Use Debt Rather Sparingly

Insider recently sold US$431k worth of stock

Insider notifies of intention to sell stock

Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings

Consensus EPS estimates fall by 14%

New minor risk - Profit margin trend

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Mimedx Group, Inc. Reports Unaudited Consolidated Impairment of Intangible Assets for the Three Months Ended December 31, 2024

Here's Why MiMedx Group (NASDAQ:MDXG) Has Caught The Eye Of Investors

Insider recently sold US$509k worth of stock

MiMedx Group, Inc. to Report Q4, 2024 Results on Feb 26, 2025

We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease

Price target increased by 9.8% to US$13.40

We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease

Investor sentiment improves as stock rises 21%

New minor risk - Share price stability

Investor sentiment improves as stock rises 32%

There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise

MiMedx Group, Inc. Raises Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. to Report Q3, 2024 Results on Oct 30, 2024

HELIOGEN's Launch And Scientific Breakthroughs Promise Growth Amid Reimbursement And Legal Challenges

Consensus EPS estimates fall by 10%

New major risk - Revenue and earnings growth

MiMedx Group, Inc. Provides Sales Guidance for the Full Year of 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

MiMedx Group, Inc. Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature- Scientific Reports

MiMedx Group, Inc. to Report Q2, 2024 Results on Jul 31, 2024

MiMedx Group, Inc. Announces the Appointment of Kim Moller to Chief Commercial Officer

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Investor sentiment improves as stock rises 18%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc., Annual General Meeting, Jun 05, 2024

MiMedx Group, Inc. to Report Q1, 2024 Results on Apr 30, 2024

MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation (RFD) from FDA